

CONTENTS

Preface	v
Contributors.....	ix
Introduction	xi
1 Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: <i>Preclinical and Clinical Modulation</i>	1
<i>G. J. Peters</i>	
2 Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: <i>Past and Future Directions</i>	29
<i>Gérard Milano</i>	
3 Biochemical Bases of the 5-Fluorouracil–Folinic Acid Interaction and of its Limitations: <i>A Retrospective Analysis</i>	37
<i>Richard G. Moran</i>	
4 Molecular Mechanisms Regulating the Expression of Thymidylate Synthase	67
<i>John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, and Edward Chu</i>	
5 Regulation of Thymidylate Synthase Gene Expression and Drug Response: <i>Posttranscriptional Regulation and Cell Population Density</i>	83
<i>Bruce J. Dolnick</i>	
6 Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action	93
<i>Janet A. Houghton</i>	
7 Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications	107
<i>Francis Lévi</i>	
8 Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents	129
<i>Alberto F. Sobrero and Ornella Belvedere</i>	
9 Noninvasive Studies of Fluoropyrimidines	139
<i>Walter Wolf, Cary A. Presant, and Victor Waluch</i>	
10 Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: <i>Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors</i>	153
<i>Shousong Cao, Gunnar Hapke, and Youcef M. Rustum</i>	

11	Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer	163
	<i>Aimery de Gramont and Christophe Louvet</i>	
12	Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases	175
	<i>Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti, and M. Adelaide Pessi</i>	
13	Fluoropyrimidines in Advanced Colorectal Cancer: <i>A Review of Six Consecutive Meta-Analyses</i>	183
	<i>Pascal Piedbois and Marc E. Buyse</i>	
14	The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer	191
	<i>Charles Erlichman, Richard M. Goldberg, and Daniel J. Sargent</i>	
15	Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: <i>The NSABP Experience</i>	199
	<i>Roy E. Smith, Eleftherios P. Mamounas, and Norman Wolmark</i>	
16	Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies	209
	<i>Paulo M. Hoff and Everardo D. Saad</i>	
17	The Development of Oral UFT with and without Leucovorin ...	219
	<i>Geert H. Blijham</i>	
18	UFT in Elderly Patients with Colorectal Cancer	229
	<i>Albert Abad, and José Luis Manzano</i>	
19	Clinical Trials of the Eniluracil/5-Fluorouracil Combination	235
	<i>Hedy L. Kindler and Richard L. Schilsky</i>	
20	Discovery and Preclinical Pharmacology of Capecitabine	249
	<i>Hideo Ishitsuka</i>	
21	Capecitabine, A Tumor-Targeting Oral Fluoropyrimidine: <i>Molecular Rationale and Clinical Validation</i>	261
	<i>Dvorit Samid</i>	
22	Capecitabine: <i>A Rationally Developed Anticancer Drug</i>	275
	<i>Daniel R. Budman</i>	
23	Preclinical and Clinical Practice of S-1 in Japan	285
	<i>Tetsuhiko Shirasaka and Tetsuo Taguchi</i>	
24	Preclinical and Clinical Practice of Low-Dose FP Therapy in Japan: <i>Japanese Use of Low-Dose FP Therapy</i>	303
	<i>Tetsuhiko Shirasaka, Akihito Tsuji, Susumu Yamamitsu, and Tetsuo Taguchi</i>	
Index	319